The lead product candidate is GSBR-1290 (Aleniglipron), an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor in two phase 2 clinical trials for obesity treatment. The pipeline also includes candidates for selective weight loss, muscle-sparing weight loss, idiopathic pulmonary fibrosis, and multiple receptor modulation programs for obesity, providing diversified upside potential across metabolic and cardiopulmonary conditions.
Cyborg Score Rationale
The company has 11 analyst covering with an average "Strong Buy" rating and recent positive Phase 2b data have driven significant upside momentum. Strong clinical validation and a well-diversified pipeline provide multiple value inflection points, though execution risk remains as a pre-commercial biotech.
Top Insights
Structure Therapeutics emerged as a top M&A target for big pharma as of January 30, 2026
Multiple major analysts raised price targets significantly in December 2025, with targets ranging from $120-$140+
Phase 2b results for Aleniglipron surpassed key efficacy and tolerability thresholds for oral GLP-1 therapies
Recently initiated Phase 1 clinical study of ACCG-2671, an oral small molecule amylin receptor agonist for obesity in December 2025
Named Competitors
Ozempic/Mounjaro — Leading injectable GLP-1 and dual GLP-1/GIP receptor agonists for obesity
VK2735 — Dual GLP-1/GIP receptor agonist candidate in clinical development